Chemed Inc (CHE) 123.62 $CHE
Walgreens Boots Growth Plans: Emerging Markets Hold Key - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:54PM CDT
Walgreens Boots (WBA) believes that its Retail Pharmacy International division will continue to gain from the multifaceted benefits it enjoys in its existing markets
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), WBA: 85.98 (-0.71), LHCG: 36.06 (+1.33)
13.3% Return Seen to Date on SmarTrend Chemed Call (CHE)
Comtex SmarTrend(R) - Mon Apr 20, 9:53AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on February 10th, 2015 at $106.76. In approximately 2 months, Chemed has returned 13.29% as of today's recent price of $120.95.
CHE: 123.62 (+0.08)
Quest Diagnostics' Pharyngitis Test Wins FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 12:50PM CDT
Quest Diagnostics' (DGX) Simplexa Direct Strep assay scores over other diagnostic testing procedures as it does not require sample extraction to achieve results, thereby saving on time and costs incurred by laboratories conducting such tests.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60)
United States Home Healthcare Market Outlook 2020
M2 - Thu Apr 16, 7:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xxtb3p/us_home) has announced the addition of the "US Home Healthcare Market Outlook 2020" report to their offering. The home healthcare market is forecasted to grow at a CAGR of approximately 7% during 2015-2020 In latest research study, US Home Healthcare Market Outlook 2020, the analysts have identified the market dynamics and clearly highlight the areas offering promising possibilities for companies to boost their growth. The growth of the market is driven by increasing federal and state funding by Medicare and Medicaid boosting the demand for healthcare services. In the present report, the market has been studied on three major grounds - by services (unskilled nursing service, rehabilitation therapy, infusion therapy, respiratory therapy), by equipment (diagnostic and monitoring home devices, medical supplies, therapeutic home healthcare, mobility assist devices) and by telehealth. Further, the growth of all the segments have been analyzed with market projections till 2020. The study also includes current market trends and drivers detailing the growth and the untapped potential of the market. Moreover, it delves into the present regulatory framework related to the industry. The report additionally provides an insight about the competitive landscape, which includes business overview, key financials and strengths and weaknesses of the top home healthcare players in the US. There's also coverage of the detailed analysis of their top services in terms of revenue generation. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Market Trends and Drivers 4. Home Healthcare Market Outlook to 2020 5. Regulatory Framework 6. Competitive Landscape - Lincare Holdings Inc. - Kindred Healthcare Inc. - Amedisys, Inc. - Apria Health Group - Chemed Corporation - National HealthCare Corporation - LHC Group, Inc. For more information visit http://www.researchandmarkets.com/research/xxtb3p/us_home
CHE: 123.62 (+0.08), LHCG: 36.06 (+1.33), AMED: 26.82 (unch), NHC: 64.53 (+0.17)
DaVita Issues 5.00% Senior Notes Worth $1.5B Due 2025 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:01PM CDT
DaVita Healthcare Partners Inc. (DVA) recently issued 5.00% senior notes worth $1.5 billion, which are scheduled to mature in 2025.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), DVA: 83.91 (+0.50), ADUS: 28.86 (+0.41)
Chemed Poised on Balanced Growth, Roto-Rooter Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 1:40PM CDT
On Apr 14, 2015, we initiated our coverage on Chemed Corporation (CHE).
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), ADUS: 28.86 (+0.41)
Almost Family (AFAM) Worth Watching: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:25AM CDT
Almost Family (AFAM) was a big mover last session, with shares rising almost 9% on the day.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80)
Chemed Up 12.3% Since SmarTrend Uptrend Call (CHE)
Comtex SmarTrend(R) - Mon Apr 13, 9:40AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on February 10th, 2015 at $106.77. In approximately 2 months, Chemed has returned 12.30% as of today's recent price of $119.90.
CHE: 123.62 (+0.08)
Quest Diagnostics (DGX) Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 12:20PM CDT
On Apr 9, 2015, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60)
Chemed To Report First-Quarter 2015 Earnings April 28, Related Conference Call To Be Held On April 29
Business Wire - Thu Apr 09, 9:47AM CDT
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the first quarter ended March 31, 2015, on Tuesday, April 28, 2015, following the close of trading on the New York Stock Exchange.
CHE: 123.62 (+0.08)
Omnicell Settles Charges, Regains Nasdaq Compliance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 12:40PM CDT
On Apr 7, 2015, we issued an updated research report on Omnicell Inc. (OMCL).
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), OMCL: 35.84 (-0.06)
AmSurg Poised on Strong Fundamentals, Strategic Buyouts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 12:50PM CDT
On Apr 3, 2015, we issued an updated research report on AmSurg Corporation (AMSG).
CHE: 123.62 (+0.08), AMSG: 65.33 (+0.04), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33)
AmSurg Buys Halifax to Boost Anesthesia Services in Florida - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 11:20AM CDT
n the recently reported fourth-quarter 2014, AmSurg's (AMSG) anesthesia services contributed 37% of the total consolidated revenue growth
CHE: 123.62 (+0.08), AMSG: 65.33 (+0.04), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33)
Almost Family (AFAM) Jumps: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 8:11AM CDT
Almost Family Inc. (AFAM) was a big mover last session, as the company saw its shares rise over 6% on the day.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80)
China Cord Blood (CO) Worth Watching: Stock Gains 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 8:25AM CDT
China Cord Blood (CO) was a big mover last session, with shares rising over 7% on the day.
CHE: 123.62 (+0.08), CO: 7.22 (+0.42)
Shares of CHE Up 15.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 23, 9:44AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on February 10th, 2015 at $106.76. In approximately 1 month, Chemed has returned 15.05% as of today's recent price of $122.83.
CHE: 123.62 (+0.08)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 29.91 (-0.42), PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), WWE: 14.48 (-0.18), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), TRNX: 26.25 (+0.01), OFIX: 36.46 (+0.10), AFFX: 12.44 (-0.16), CHE: 123.62 (+0.08), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), IART: 61.31 (+0.84), SONC: 30.83 (-0.21), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), ANAC: 64.49 (-2.10), XSD: 85.14 (-2.91), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), IPAR: 31.75 (-0.88), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), NSIT: 28.68 (+0.01), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), FLDM: 42.47 (-0.73), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), SWHC: 15.01 (+0.10), OCFC: 17.32 (+0.42)
Is Chemed (CHE) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 19, 7:54AM CDT
Chemed in the Medical Home Care space could be a very interesting choice for investors seeking a name in a great industry segment
CHE: 123.62 (+0.08)
Omnicell Tweaks '15 View on Legal Issues, Impending Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 3:01PM CDT
Omnicell, Inc. (OMCL) has provided an update on its financial guidance for first quarter and full-year 2015.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), OMCL: 35.84 (-0.06)
Walgreens Boots Growth Plans: Emerging Markets Hold Key - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:54PM CDT
Walgreens Boots (WBA) believes that its Retail Pharmacy International division will continue to gain from the multifaceted benefits it enjoys in its existing markets
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), WBA: 85.98 (-0.71), LHCG: 36.06 (+1.33)
13.3% Return Seen to Date on SmarTrend Chemed Call (CHE)
Comtex SmarTrend(R) - Mon Apr 20, 9:53AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on February 10th, 2015 at $106.76. In approximately 2 months, Chemed has returned 13.29% as of today's recent price of $120.95.
CHE: 123.62 (+0.08)
Quest Diagnostics' Pharyngitis Test Wins FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 12:50PM CDT
Quest Diagnostics' (DGX) Simplexa Direct Strep assay scores over other diagnostic testing procedures as it does not require sample extraction to achieve results, thereby saving on time and costs incurred by laboratories conducting such tests.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60)
United States Home Healthcare Market Outlook 2020
M2 - Thu Apr 16, 7:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xxtb3p/us_home) has announced the addition of the "US Home Healthcare Market Outlook 2020" report to their offering. The home healthcare market is forecasted to grow at a CAGR of approximately 7% during 2015-2020 In latest research study, US Home Healthcare Market Outlook 2020, the analysts have identified the market dynamics and clearly highlight the areas offering promising possibilities for companies to boost their growth. The growth of the market is driven by increasing federal and state funding by Medicare and Medicaid boosting the demand for healthcare services. In the present report, the market has been studied on three major grounds - by services (unskilled nursing service, rehabilitation therapy, infusion therapy, respiratory therapy), by equipment (diagnostic and monitoring home devices, medical supplies, therapeutic home healthcare, mobility assist devices) and by telehealth. Further, the growth of all the segments have been analyzed with market projections till 2020. The study also includes current market trends and drivers detailing the growth and the untapped potential of the market. Moreover, it delves into the present regulatory framework related to the industry. The report additionally provides an insight about the competitive landscape, which includes business overview, key financials and strengths and weaknesses of the top home healthcare players in the US. There's also coverage of the detailed analysis of their top services in terms of revenue generation. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Market Trends and Drivers 4. Home Healthcare Market Outlook to 2020 5. Regulatory Framework 6. Competitive Landscape - Lincare Holdings Inc. - Kindred Healthcare Inc. - Amedisys, Inc. - Apria Health Group - Chemed Corporation - National HealthCare Corporation - LHC Group, Inc. For more information visit http://www.researchandmarkets.com/research/xxtb3p/us_home
CHE: 123.62 (+0.08), LHCG: 36.06 (+1.33), AMED: 26.82 (unch), NHC: 64.53 (+0.17)
DaVita Issues 5.00% Senior Notes Worth $1.5B Due 2025 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:01PM CDT
DaVita Healthcare Partners Inc. (DVA) recently issued 5.00% senior notes worth $1.5 billion, which are scheduled to mature in 2025.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), DVA: 83.91 (+0.50), ADUS: 28.86 (+0.41)
Chemed Poised on Balanced Growth, Roto-Rooter Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 1:40PM CDT
On Apr 14, 2015, we initiated our coverage on Chemed Corporation (CHE).
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), ADUS: 28.86 (+0.41)
Almost Family (AFAM) Worth Watching: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:25AM CDT
Almost Family (AFAM) was a big mover last session, with shares rising almost 9% on the day.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80)
Chemed Up 12.3% Since SmarTrend Uptrend Call (CHE)
Comtex SmarTrend(R) - Mon Apr 13, 9:40AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on February 10th, 2015 at $106.77. In approximately 2 months, Chemed has returned 12.30% as of today's recent price of $119.90.
CHE: 123.62 (+0.08)
Quest Diagnostics (DGX) Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 12:20PM CDT
On Apr 9, 2015, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60)
Chemed To Report First-Quarter 2015 Earnings April 28, Related Conference Call To Be Held On April 29
Business Wire - Thu Apr 09, 9:47AM CDT
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the first quarter ended March 31, 2015, on Tuesday, April 28, 2015, following the close of trading on the New York Stock Exchange.
CHE: 123.62 (+0.08)
Omnicell Settles Charges, Regains Nasdaq Compliance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 12:40PM CDT
On Apr 7, 2015, we issued an updated research report on Omnicell Inc. (OMCL).
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), OMCL: 35.84 (-0.06)
AmSurg Poised on Strong Fundamentals, Strategic Buyouts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 12:50PM CDT
On Apr 3, 2015, we issued an updated research report on AmSurg Corporation (AMSG).
CHE: 123.62 (+0.08), AMSG: 65.33 (+0.04), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33)
AmSurg Buys Halifax to Boost Anesthesia Services in Florida - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 11:20AM CDT
n the recently reported fourth-quarter 2014, AmSurg's (AMSG) anesthesia services contributed 37% of the total consolidated revenue growth
CHE: 123.62 (+0.08), AMSG: 65.33 (+0.04), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33)
Almost Family (AFAM) Jumps: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 8:11AM CDT
Almost Family Inc. (AFAM) was a big mover last session, as the company saw its shares rise over 6% on the day.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80)
China Cord Blood (CO) Worth Watching: Stock Gains 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 8:25AM CDT
China Cord Blood (CO) was a big mover last session, with shares rising over 7% on the day.
CHE: 123.62 (+0.08), CO: 7.22 (+0.42)
Shares of CHE Up 15.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 23, 9:44AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on February 10th, 2015 at $106.76. In approximately 1 month, Chemed has returned 15.05% as of today's recent price of $122.83.
CHE: 123.62 (+0.08)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 29.91 (-0.42), PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), WWE: 14.48 (-0.18), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), TRNX: 26.25 (+0.01), OFIX: 36.46 (+0.10), AFFX: 12.44 (-0.16), CHE: 123.62 (+0.08), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), IART: 61.31 (+0.84), SONC: 30.83 (-0.21), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), ANAC: 64.49 (-2.10), XSD: 85.14 (-2.91), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), IPAR: 31.75 (-0.88), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), NSIT: 28.68 (+0.01), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), FLDM: 42.47 (-0.73), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), SWHC: 15.01 (+0.10), OCFC: 17.32 (+0.42)
Is Chemed (CHE) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 19, 7:54AM CDT
Chemed in the Medical Home Care space could be a very interesting choice for investors seeking a name in a great industry segment
CHE: 123.62 (+0.08)
Omnicell Tweaks '15 View on Legal Issues, Impending Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 3:01PM CDT
Omnicell, Inc. (OMCL) has provided an update on its financial guidance for first quarter and full-year 2015.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), OMCL: 35.84 (-0.06)
